• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Fluoxetine Plus CBT for Somatic Symptom Disorder

Fluoxetine Plus CBT for Somatic Symptom Disorder

November 1, 2017
Shirley Tsai
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Shirley Tsai PharmD candidate (2018) Ms. Tsai has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Fallon BA et al, Am J Psychiatry 2017;174(8):756–764

Somatic symptom disorder (formerly known as hypochondriasis) is pretty common, with a prevalence of 5%–7%, and is much more likely to afflict women than men, with a gender ratio of about 10:1. While both psychotherapy and SSRI treatment are helpful, there is limited evidence about the efficacy of combining therapy with medication. A new study sought to remedy this gap.

Researchers recruited 195 people with hypochondriasis (the study occurred before DSM-5) and randomly assigned them to one of four groups: placebo, cognitive behavioral therapy (CBT), fluoxetine, or combination treatment with both CBT and fluoxetine. CBT sessions were delivered from a scripted manual to participants in six 60-minute sessions on a weekly basis, followed by 2 biweekly and then 3 monthly boosters by experienced therapists. Fluoxetine and placebo groups were both given 20- to 30-minute medication management appointments with psychiatrists. Fluoxetine was started at 10 mg QD and gradually increased up to 80 mg QD as tolerated. Patients in the combination group met with both a therapist and psychiatrist. Response was defined as a 25% improvement in symptom severity.

Hypochondriasis symptoms were evaluated at weeks 6, 12, and 24. Based on primary outcome measures at week 24, patients assigned to combination treatment had the highest response rate (47.2%)—higher than the therapy group (39.6%) or the placebo group (29.5%), but not statistically significantly higher than the fluoxetine group (44.4%). However, on a variety of secondary measures, the advantage of combination treatment over fluoxetine alone was less pronounced, and in some cases fluoxetine alone seemed more effective. Interestingly, patients in the fluoxetine-alone group ended up with a mean dose of 40 mg/day; this was higher than patients in the combination group, who took a mean dose of 30.9 mg/day. Adverse events were mild, and were similar in all four treatment groups.

TCPR’s Take
Fluoxetine was effective for symptoms of hypochondriasis. Adding CBT provided only a small additional benefit over fluoxetine alone, although this benefit might have been greater if the dose of fluoxetine in the combination group had been higher. Bottom line, you should consider fluoxetine treatment for your patients with somatic symptom disorder, with or without added CBT.
General Psychiatry
KEYWORDS research_updates
    Shirley Tsai

    More from this author
    www.thecarlatreport.com
    Issue Date: November 1, 2017
    SUBSCRIBE NOW
    Table Of Contents
    Closing a Practice: Some Practical Suggestions
    Financial Planning for Retirement
    Aripiprazole Augmentation May Improve Remission Rates in MDD
    Fluoxetine Plus CBT for Somatic Symptom Disorder
    CME Post-Test - Retirement, TCPR, November 2017
    Note From the Editor-in-Chief
    Retirement Toolkits
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.